Anti-CD155 antibodies and their applications
Through hybridoma technology screening and humanized CDR mutations, anti-CD155 antibodies that do not induce apoptosis were developed, solving the problems of existing antibodies' safety risks and screening difficulty, and achieving efficient and safe CD155 blocking effect.
Patent Information
- Application Number
- CN202211600706.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-12
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-12-12
AI Technical Summary
The existing antibodies that block CD155 receptors have a safety risk of inducing apoptosis of CD155-positive normal tissue cells, and screening and blocking CD155 binding to its receptors is difficult, making it difficult to develop antibodies targeting CD155.
High-affinity anti-CD155 monoclonal antibodies were screened through hybridoma technology, and the constant region of their murine-derived antibodies was humanized, retained the variable region, and further CDR mutations were carried out to obtain humanized antibodies with mature affinity to ensure that cells were not inducible Apoptosis and effectively block the binding of CD155 to its receptor.
The obtained chimeric antibodies and humanized antibodies can specifically bind to the CD155 receptor, block the binding of CD155 to TIGIT, CD96, and CD226, effectively treat or prevent CD155-mediated diseases, and achieve high safety at less doses. Sex, low toxic side effects.
Smart Images

Figure CN116284395B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to an anti-CD155 antibody and application thereof. Background Art
[0002] CD155, also known as NECL-5 or PVR, is a type I transmembrane protein. Its extracellular segment contains one IgV domain, two IgC domains, and the intracellular segment contains an ITIM motif. Studies have found that CD155 can fall off the cell surface to form soluble CD155 protein. CD155 is expressed on the surface of tissue cells such as monocytes and dendritic cells, and is upregulated in a variety of tumor tissues. Studies have shown that CD155 promotes tumor invasion and metastasis, and high expression of CD155 is associated with poor tumor prognosis.
[0003] NK cells and T cells express a variety of CD155 receptors on their surfaces, including TIGIT, CD96, and CD226, of which TIGIT and CD96 are inhibitory receptors and CD226 is an activating receptor. Immune checkpoint antibodies targeting TIGIT and CD96 have entered the clinical trial stage, of which Roche's TIGIT monoclonal antibody is the fastest-progressing, and is currently in Phase III clinical trials. CD155 shed from the cell surface can bind to CD226, downregulate CD226, and weaken the anti-cancer function of NK cells and T cells. Eli Lily is currently developing agonistic CD226 antibodies.
[0004] Studies have found that patients with non-small cell lung cancer and melanoma with high expression of CD155 have a worse prognosis and a worse response to PD-1 / L1 therapy. Therefore, it is necessary to develop an antibody drug targeting CD155. On the one hand, it is suitable for patients with PD-L1 negative, and on the other hand, it improves the response to PD-1 / L1 therapy. So far, only one CD155 antibody has entered the clinical trial stage, namely Nectin's NTX-1088 antibody (named NB1088 in the early discovery stage). This antibody is an IgG4 subtype and can block CD155 from binding to its receptors TIGIT, CD96, and CD226. Our research found that the antibody strongly induced apoptosis of CD155-positive cells, while human peripheral blood mononuclear cells and a variety of normal tissue cells expressed CD155, suggesting that the antibody may have safety risks in clinical use. Another CD155 antibody commonly used in scientific research, SKII.4, is also a blocking antibody that can block the binding of CD155 to its receptor. Our research found that the antibody also strongly induced apoptosis of CD155-positive cells.
[0005] Therefore, further research is needed to develop a safe antibody drug targeting CD155. Summary of the invention
[0006] This application is filed based on the inventor's discovery of the following issues and facts:
[0007] CD155 is expressed on the surface of tissue cells such as monocytes and dendritic cells, and is upregulated in a variety of tumor tissues. CD155 promotes tumor invasion and metastasis, and high expression of CD155 is associated with poor tumor prognosis. However, since CD155 binds to three receptors, TIGIT, CD96, and CD226, it is difficult to screen blocking anti-CD155 monoclonal antibodies. Secondly, the existing antibodies that block CD155 receptors still have the safety risk of inducing apoptosis of CD155-positive normal tissue cells. Therefore, it is difficult to design and develop monoclonal antibodies against CD155.
[0008] The inventors of this application successfully obtained a blocking CD155 antibody that does not induce cell apoptosis through screening. Specifically, this study screened a series of high-affinity anti-CD155 monoclonal antibodies that block the binding of CD155 to its receptors TIGIT, CD96, CD226, etc. through hybridoma technology, and humanized the constant region of the mouse anti-CD155 monoclonal antibody, retaining the variable region of the mouse anti-CD155 monoclonal antibody, to obtain a series of anti-CD155 chimeric monoclonal antibodies; on this basis, the inventors further humanized the framework region in the mouse variable region to obtain a humanized CD155 antibody, and further, discovered The inventors mutated the CDR of the humanized CD155 antibody to obtain an affinity-matured humanized CD155 antibody. The inventors found that the chimeric antibody, humanized antibody and affinity-matured humanized antibody obtained in the present application can not only specifically target and bind to the CD155 receptor, block the binding of CD155 to its receptors TIGIT, CD96, CD226, etc., effectively treat and / or prevent CD155-mediated related diseases, such as tumors, but also have the characteristic of not inducing CD155 cell apoptosis.
[0009] Therefore, in the first aspect of the present invention, the present invention proposes an antibody or antigen-binding fragment. According to an embodiment of the present invention, the antibody or antigen-binding fragment includes a CDR sequence selected from at least one of the following or an amino acid sequence having at least 80% identity therewith: heavy chain variable region CDR sequence: SEQ ID NO: 1-3, 7-9, 13-15 and 19-21, light chain variable region CDR sequence: SEQ IN NO: 4-6, 10-12, 16-18 and 22-24. The antibody or antigen-binding fragment according to an embodiment of the present invention is an affinity-matured humanized antibody, which has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0010] In the second aspect of the present invention, the present invention provides a nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule encodes the antibody or antigen-binding fragment described in the first aspect. The antibody or antigen-binding fragment encoded by the nucleic acid molecule according to the embodiment of the present invention has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0011] In the third aspect of the present invention, the present invention proposes an expression vector. According to an embodiment of the present invention, the nucleic acid molecule described in the second aspect is carried. The expression vector may include an optional control sequence, and the control sequence is operably connected to the nucleic acid molecule. Among them, the control sequence is one or more control sequences that can guide the expression of the nucleic acid molecule in the host. The expression vector proposed in the embodiment of the present invention can efficiently express the antibody or antigen-binding fragment in a suitable host cell, and the antibody or antigen-binding fragment has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0012] In the fourth aspect of the present invention, the present invention proposes a method for preparing the antibody or antigen-binding fragment described in the first aspect. According to an embodiment of the present invention, it includes: introducing the expression vector described in the third aspect into a cell; culturing the cell under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment. The method proposed in the embodiment of the present invention can effectively obtain the antibody or antigen-binding fragment, which has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0013] In the fifth aspect of the present invention, the present invention proposes a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the nucleic acid described in the second aspect, or the expression vector described in the third aspect, or can express the antibody or antigen-binding fragment described in the first aspect. The recombinant cell is obtained by transfecting or transforming the expression vector. According to some specific embodiments of the present invention, the recombinant cell can efficiently and massively express the above-mentioned antibody or antigen-binding fragment under appropriate conditions, and the antibody or antigen-binding fragment has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0014] In the sixth aspect of the present invention, the present invention proposes an immunoconjugate. According to an embodiment of the present invention, the immunoconjugate includes the antibody or antigen binding fragment described in the first aspect, and a therapeutic agent. As mentioned above, the antibody or antigen binding fragment of the embodiment of the present invention can effectively bind to CD155 protein and block CD155 protein from binding to its receptor. Therefore, the immunoconjugate containing the antibody or antigen binding fragment can also bind to human or monkey CD155 protein. The immunoconjugate has a good effect of preventing and / or treating CD155-mediated diseases, and does not induce apoptosis of CD155-positive cells. It has low toxicity and side effects and has higher safety.
[0015] In the seventh aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, it includes the above-mentioned antibody, nucleic acid molecule, expression vector or recombinant cell. As mentioned above, the antibody or antigen binding fragment of the embodiment of the present invention can effectively bind to CD155 protein, and block CD155 protein from binding to its receptor, and will not induce apoptosis of CD155 positive cells. Therefore, the composition containing the above-mentioned substances can also effectively block CD155 protein from binding to its receptor, and the antibody or antigen binding fragment has a good effect of preventing and / or treating CD155-mediated diseases, and will not induce apoptosis of CD155 positive cells.
[0016] In the eighth aspect of the present invention, the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment thereof, nucleic acid molecule, expression vector, recombinant cell or composition in the preparation of a drug, and the drug is used to prevent and / or treat CD155-related diseases. As mentioned above, the antibody or antigen-binding fragment of the embodiment of the present invention can effectively bind to CD155 protein, and block CD155 protein from binding to its receptor, and will not induce CD155 positive cell apoptosis. Therefore, the drug containing the above-mentioned substance can also effectively block CD155 protein from binding to its receptor, and the antibody or antigen-binding fragment has a good effect of preventing and / or treating CD155-mediated diseases, and will not induce CD155 positive cell apoptosis.
[0017] In the ninth aspect of the present invention, the present invention proposes a drug. According to an embodiment of the present invention, the drug includes the antibody nucleic acid molecule, expression vector, recombinant cell or composition described above. As mentioned above, the antibody or antigen binding fragment of the embodiment of the present invention can effectively bind to CD155 protein, and block CD155 protein from binding to its receptor, and will not induce apoptosis of CD155 positive cells. Therefore, the drug containing the above-mentioned substance can also effectively block CD155 protein from binding to its receptor, and the antibody or antigen binding fragment has a good effect of preventing and / or treating CD155-mediated diseases, and will not induce apoptosis of CD155 positive cells.
[0018] In the tenth aspect of the present invention, the present invention proposes the use of the above-mentioned antibody or antigen binding fragment in the preparation of a kit. According to an embodiment of the present invention, the kit is used to detect CD155. As mentioned above, the antibody or antigen binding fragment of the embodiment of the present invention can effectively bind to human or monkey CD155 protein and block the CD155 protein from binding to its receptor. Therefore, the antibody or antigen binding fragment can be used to prepare a kit for detecting CD155 protein, and the kit can effectively detect CD155 protein qualitatively or quantitatively.
[0019] In the eleventh aspect of the present invention, the present invention proposes a kit for detecting CD155. According to an embodiment of the present invention, the kit contains the above-mentioned antibody or antigen-binding fragment thereof. As mentioned above, the antibody or antigen-binding fragment of the embodiment of the present invention can effectively bind to human or monkey CD155 protein and block the CD155 protein from binding to its receptor. Therefore, the kit containing the antibody or antigen-binding fragment can effectively detect the CD155 protein qualitatively or quantitatively.
[0020] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0022] Figure 1 The flow cytometry results of different concentrations of mouse CD155 antibodies binding to CHO-K1-human CD155 cells expressing human CD155 protein and CHO-K1-Rhesus CD155 cells expressing monkey CD155 protein according to a specific embodiment of the present invention;
[0023] Figure 2 This is a graph showing the results of different concentrations of mouse CD155 antibodies blocking TIGIT-Fc, CD96-Fc, and CD226-Fc from binding to CHO-K1-human CD155 cells expressing human CD155 protein according to a specific embodiment of the present invention;
[0024] Figure 3 This is a graph showing the ELISA results of different concentrations of mouse CD155 antibodies blocking TIGIT, CD96, and CD266 from binding to recombinantly expressed human CD155 protein according to a specific embodiment of the present invention;
[0025] Figure 4 The flow cytometry results of different concentrations of human-mouse chimeric CD155 antibodies binding to CHO-K1-huamn CD155 and CHO-K1-Rhesus CD155 cells according to a specific embodiment of the present invention are shown;
[0026] Figure 5 ELISA results of affinity-matured humanized CD155 antibodies of different concentrations binding to human and monkey CD155 proteins according to a specific embodiment of the present invention;
[0027] Figure 6The ELISA results of different concentrations of affinity-matured humanized CD155 antibodies blocking TIGIT, CD96, and CD226 from binding to human or monkey CD155 proteins expressed by CHO-K1-huamn CD155 and CHO-K1-Rhesus CD155 cells according to a specific embodiment of the present invention are shown;
[0028] Figure 7 Figure 2 is a flow cytometry result diagram of affinity matured humanized CD155 antibodies of different concentrations binding to CHO-K1-human CD155 and CHO-K1-Rhesus CD155 according to a specific embodiment of the present invention;
[0029] Figure 8 This is a result diagram showing that the humanized CD155 antibody according to a specific embodiment of the present invention promotes apoptosis of U-937-CD155 cells;
[0030] Fig. 9 This is a graph showing the detection results of humanized CD155 antibody promoting immune reconstitution of mice against human tumors according to a specific embodiment of the present invention. DETAILED DESCRIPTION
[0031] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0032] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0033] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0034] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0035] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. The abbreviations for amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.
[0036] In the present invention, unless otherwise specified, the term antigen-binding fragment used is also referred to as "antibody fragment". Antibody fragments generally refer to antigen-binding antibody fragments and may include a portion of an intact antibody, generally an antigen-binding region or a variable region. Examples of antibody fragments include Fab, Fab', F(ab')2, Fv or scFv, diabodies, linear antibodies, single-chain antibody molecules, etc.
[0037] The term "complementarity determining region" or "CDR" or "CDR sequence" refers to the amino acid sequence in an antibody that is responsible for antigen binding, for example, generally including: amino acid residues around 23-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable region, and around 31-35B (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health). of Health, Bethesda, MD. (1991)); and / or from "hypervariable loops" (e.g., amino acid residues around 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable region, and 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable region (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
[0038] The term "conservatively modified amino acid sequence" refers to amino acid modifications that do not significantly affect or alter the binding properties of an antibody comprising the amino acid sequence, including amino acid substitutions, additions and deletions. Modifications can be introduced into the antibodies of the invention by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been identified in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR region of an antibody of the invention may be replaced by other amino acid residues from the same side chain family, and the retained function of the altered antibody may be tested using the functional assays described herein. Preferably, conservative modifications are no more than 1 or 2 in number.
[0039] With respect to polypeptides, the term "substantial homology" means that two polypeptides or designated sequences thereof are identical in at least about 80% of their amino acids, usually at least about 90% to 95%, and more preferably at least about 98% to 99.5% when optimally aligned and compared (with appropriate insertions or deletions of nucleotides).
[0040] The % identity between two sequences varies with the number of identical positions shared by the sequences when the sequences are optimally aligned (i.e., % homology = number of identical positions / total number of positions x 100), wherein optimal alignment is determined by taking into account the number of gaps that need to be introduced to achieve optimal alignment of the two sequences and the length of each gap. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
[0041] Under the premise of not substantially affecting the activity of the antibody (retaining at least 95% of the activity), those skilled in the art can replace, add and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present invention to obtain variants of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region. The sequence of the variant of the present invention can have at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% consistency (or homology) with the reference sequence. The sequence consistency of the present invention can be measured using sequence analysis software. For example, the computer program BLAST with default parameters is used, especially BLASTP or TBLASTN. The amino acid sequences described in the present invention are all shown in an N-terminal to C-terminal manner.
[0042] As previously mentioned, the antibodies of the present invention may be full length (e.g., IgG1 or IgG4 antibodies) or may comprise only an antigen binding portion (e.g., Fab, F(ab')2 or scFv fragments), or may be modified to affect function. The present invention includes anti-CD155 antibodies with modified glycosylation patterns. In some applications, it may be useful to modify to remove undesirable glycosylation sites, or to remove fucose moieties on oligosaccharide chains to, for example, enhance antibody-dependent cellular cytotoxicity (ADCC) function. In other applications, galactosylation may be performed to alter complement-dependent cytotoxicity (CDC).
[0043] The term "functional fragment" as used herein refers in particular to antibody fragments such as Fv, scFv (sc means single chain), Fab, F(ab')2, Fab', scFv-Fc fragments or diabodies, or any fragments that should be able to increase half-life by chemical modification or by incorporation into liposomes, such as the addition of poly (alkylene) glycols, such as polyethylene glycol ("PEGylation, PEGylation") (called Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG or Fab'-PEG PEGylated fragments) ("PEG" is polyethylene glycol), the fragment has CD155 binding activity. Preferably, the functional fragment will be composed of or contain a partial sequence of the heavy chain variable region or light chain variable region of the antibody from which it is derived, and the partial sequence is sufficient to retain the same binding specificity and sufficient affinity as the antibody from which it is derived, preferably at least equal to 1 / 100 of the affinity of the antibody from which it is derived, and at least equal to 1 / 10 in a more preferred manner. Such functional fragments will contain a minimum of 5 amino acids, and preferably 10, 15, 25, 50 and 100 consecutive amino acids of the antibody sequence from which they are derived.
[0044] In one aspect of the present invention, the present invention proposes an antibody or antigen-binding fragment, including a CDR sequence selected from at least one of the following or an amino acid sequence having at least 80% identity therewith: heavy chain variable region CDR sequence: SEQ ID NO: 1-3, 7-9, 13-15 and 19-21, light chain variable region CDR sequence: SEQ IN NO: 4-6, 10-12, 16-18 and 22-24. The antibody or antigen-binding fragment according to the embodiment of the present invention is an affinity-matured humanized antibody, which has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0045] In a preferred embodiment of the present invention, in order to further improve the bioacceptability, specificity and efficacy of the antibody, the antibody is humanized. Furthermore, the inventor performs affinity maturation treatment on the humanized antibody, such as mutating the CDR to obtain an affinity matured antibody. The term "chimeric antibody" refers to a recombinant antibody obtained by replacing the constant region amino acid sequence of a monoclonal antibody from one species (such as a mouse) with the constant region of an antibody from another species (such as a human) using recombinant DNA technology. The term "humanized antibody" refers to a recombinant antibody obtained by replacing all non-CDR (Fv framework region (FR)) amino acid sequences of the constant region and variable region of a monoclonal antibody from one species (such as a mouse) with non-CDR amino acid sequences of the constant region and variable region of an antibody from another species (such as a human) using recombinant DNA technology. That is, when the constant region of an antibody is humanized, it is called a chimeric antibody, and when the non-CDR amino acid sequences of the constant region and variable region are all humanized, it is called a humanized antibody. The method of humanization can be carried out with reference to conventional antibody engineering technology, which will not be repeated here. "Antibody affinity maturation" refers to the random mutation of the amino acids in the CDR region of the antibody, and obtaining antibodies with higher affinity for the corresponding antigen by screening the mutant library.
[0046] According to some specific embodiments of the present invention, the above-mentioned antibody or antigen-binding fragment further comprises at least one of the following additional technical features:
[0047] According to some specific embodiments of the present invention, the antibody or antigen-binding fragment comprises: a heavy chain variable region CDR1 selected from at least one of the amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 19 and their conservatively modified forms of amino acid sequences; a heavy chain variable region CDR2 selected from at least one of the amino acid sequences shown in SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 20 and their conservatively modified forms of amino acid sequences; and a heavy chain variable region CDR3 selected from at least one of the amino acid sequences shown in SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 21 and their conservatively modified forms of amino acid sequences.
[0048] According to some specific embodiments of the present invention, the antibody or antigen-binding fragment may also include a light chain variable region CDR1 selected from at least one of the amino acid sequences shown in SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:22 and their conservatively modified forms of amino acid sequences; a light chain variable region CDR2 selected from at least one of the amino acid sequences shown in SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:23 and their conservatively modified forms of amino acid sequences; and a light chain variable region CDR3 selected from at least one of the amino acid sequences shown in SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:18, SEQ ID NO:24 and their conservatively modified forms of amino acid sequences.
[0049] According to some specific embodiments of the present invention, the antibody or antigen-binding fragment comprises: 1) a heavy chain variable region CDR1 as shown in SEQ ID NO: 1, a heavy chain variable region CDR2 as shown in SEQ ID NO: 2, a heavy chain variable region CDR3 as shown in SEQ ID NO: 3, a light chain variable region CDR1 as shown in SEQ ID NO: 4, a light chain variable region CDR2 as shown in SEQ ID NO: 5, and a light chain variable region CDR3 as shown in SEQ ID NO: 6; or 2) a heavy chain variable region CDR1 as shown in SEQ ID NO: 7, a heavy chain variable region CDR2 as shown in SEQ ID NO: 8, a heavy chain variable region CDR3 as shown in SEQ ID NO: 9, a light chain variable region CDR1 as shown in SEQ ID NO: 10, a light chain variable region CDR2 as shown in SEQ ID NO: 11, and a light chain variable region CDR3 as shown in SEQ ID NO: 12; or 3) a heavy chain variable region CDR1 as shown in SEQ ID NO: 13, a heavy chain variable region CDR2 as shown in SEQ ID NO: 14, a heavy chain variable region CDR3 as shown in SEQ ID NO: 15, and a light chain variable region CDR3 as shown in SEQ ID NO: 16. NO:16, the light chain variable region CDR1 shown in SEQ ID NO:17, and the light chain variable region CDR3 shown in SEQ ID NO:18; or 4) the heavy chain variable region CDR1 shown in SEQ ID NO:19, the heavy chain variable region CDR2 shown in SEQ ID NO:20, the heavy chain variable region CDR3 shown in SEQ ID NO:21, the light chain variable region CDR1 shown in SEQ ID NO:22, the light chain variable region CDR2 shown in SEQ ID NO:23, and the light chain variable region CDR3 shown in SEQ ID NO:24.
[0050] According to some specific embodiments of the present invention, the antibody or antigen-binding fragment comprises: i) a heavy chain variable region, which has an amino acid sequence that is at least 80% homologous to at least one of the amino acid sequences shown in SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31 and their conservatively modified forms; and / or ii) a light chain variable region, which has an amino acid sequence that is at least 80% homologous to at least one of the amino acid sequences shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 and their conservatively modified forms.
[0051] According to some specific embodiments of the present invention, the heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homologous to the heavy chain variable region selected from i); the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homologous to the light chain variable region selected from ii).
[0052] According to some specific embodiments of the present invention, the antibody or antigen-binding fragment includes: 1) a heavy chain variable region as shown in SEQ ID NO: 25, and a light chain variable region as shown in SEQ ID NO: 26; or 2) a heavy chain variable region as shown in SEQ ID NO: 27, and a light chain variable region as shown in SEQ ID NO: 28; or 3) a heavy chain variable region as shown in SEQ ID NO: 29, and a light chain variable region as shown in SEQ ID NO: 30; or 4) a heavy chain variable region as shown in SEQ ID NO: 31, and a light chain variable region as shown in SEQ ID NO: 32.
[0053] According to some specific embodiments of the present invention, the antibody contains at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a human antibody, a primate antibody or a mutant thereof.
[0054] According to some specific embodiments of the present invention, the light chain constant region and the heavy chain constant region of the antibody are both derived from human IgG antibodies or mutants thereof.
[0055] According to some specific embodiments of the present invention, the light chain constant region and the heavy chain constant region of the antibody are both derived from human IgG1 antibody, human IgG4 antibody or mutants thereof.
[0056] According to some specific embodiments of the present invention, the antibody has a heavy chain constant region with an amino acid sequence as shown in SEQ ID NO:41, 42 or 43 and / or a light chain constant region with an amino acid sequence as shown in SEQ ID NO:44.
[0057] According to some specific embodiments of the present invention, the heavy chain has an amino acid sequence shown in any one of SEQ ID NOs: 33, 35, 37 and 39 and the light chain has an amino acid sequence shown in any one of SEQ ID NOs: 34, 36, 38 and 40.
[0058] According to some specific embodiments of the present invention, the antibody is a monoclonal antibody, a murine antibody, a chimeric antibody, a humanized antibody, a human antibody, a human antibody, Fv, a single-chain antibody (scFv), Fab, Fab', Fab'-SH or F(ab')2.
[0059] According to some specific embodiments of the present invention, the antibody or its antigen-binding fragment is capable of binding to the amino acid sequence shown in SEQ ID NO: 73 and / or 74.
[0060] Nucleic acids encoding the heavy and / or light chains of the antibodies of the present invention are within the scope of the present invention. Based on the amino acid sequences of the heavy and / or light chains, those skilled in the art can easily obtain the corresponding nucleic acid sequences.
[0061] Therefore, in another aspect of the present invention, the present invention provides a nucleic acid molecule encoding the antibody or antigen-binding fragment described in the first aspect. According to some specific embodiments of the present invention, the antibody or antigen-binding fragment encoded by the nucleic acid molecule has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0062] According to some specific embodiments of the present invention, the above nucleic acid molecule may further include at least one of the following additional technical features:
[0063] According to some specific embodiments of the present invention, the nucleic acid molecule is DNA.
[0064] It should be noted that, for the nucleic acids mentioned in the specification and claims of the present invention, those skilled in the art should understand that they actually include any one or both of the complementary double strands. For convenience, in the specification and claims, although only one strand is given in most cases, the other strand complementary thereto is actually disclosed. In addition, the nucleic acid sequence in the present application includes a DNA form or an RNA form, and disclosing one of them means that the other is also disclosed.
[0065] In another aspect of the present invention, the present invention proposes an expression vector, the expression vector carries the aforementioned nucleic acid molecule. The expression vector may include an optional control sequence, the control sequence is operably connected to the nucleic acid molecule. Wherein, the control sequence is one or more control sequences that can guide the expression of the nucleic acid molecule in the host. The expression vector proposed in the embodiment of the present invention can efficiently express the antibody or antigen binding fragment in a suitable host cell, and the antibody or antigen binding fragment has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce CD155 positive cell apoptosis, its toxic side effects are low, and it has higher safety. When the above-mentioned nucleic acid molecule is connected to the vector, the nucleic acid molecule can be directly or indirectly connected to the control element on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. Of course, the nucleic acid molecule can be operably connected to the control element. "Operably connected" herein means connecting the foreign gene to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their expected functions of regulating the transcription and translation of the foreign gene. Of course, the nucleic acid molecules used to encode antibodies or antigen-binding fragments can be inserted into different vectors independently, and it is common to insert them into the same vector. Commonly used vectors can be, for example, plasmids, bacteriophages, etc. For example, Plasmid-X plasmid.
[0066] In one aspect of the present invention, the present invention proposes a method for preparing the above-mentioned antibody or antigen-binding fragment, comprising: introducing the above-mentioned expression vector into cells; culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment. The method proposed according to some specific embodiments of the present invention can effectively obtain the antibody or antigen-binding fragment, which has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0067] According to some specific embodiments of the present invention, the method for preparing the above-mentioned antibody or antigen-binding fragment may also include at least one of the following additional technical features:
[0068] According to some specific embodiments of the present invention, the cells are not particularly limited, and either prokaryotic cells or eukaryotic cells can be used. When the cells are eukaryotic cells, such as mammalian cells, the expression efficiency of the recombinant antibody is higher.
[0069] According to some specific embodiments of the present invention, the cell is a eukaryotic cell.
[0070] According to some specific embodiments of the present invention, the eukaryotic cell is a mammalian cell. According to some specific embodiments of the present invention, when the cell is a eukaryotic cell, such as a mammalian cell, the expression efficiency of the recombinant antibody is higher.
[0071] According to some specific embodiments of the present invention, the eukaryotic cells do not include animal germ cells, fertilized eggs or embryonic stem cells.
[0072] In another aspect of the present invention, the present invention proposes a recombinant cell, the recombinant cell contains the aforementioned nucleic acid, or expression vector, or can express the aforementioned antibody or antigen binding fragment. The recombinant cell is obtained by transfecting or transforming the expression vector. According to some specific embodiments of the present invention, the recombinant cell can efficiently and massively express the above-mentioned antibody or antigen binding fragment under suitable conditions, and the antibody or antigen binding fragment has stronger specificity, longer half-life and stronger efficacy, can bind to human or monkey CD155 protein, and block CD155 from binding to its receptors TIGIT, CD96, CD226, etc., can effectively treat or prevent CD155-mediated related diseases at a lower dosage, and will not induce apoptosis of CD155-positive cells, and has low toxic side effects and higher safety.
[0073] It should be noted that the recombinant cells of the present invention are not particularly limited and may be prokaryotic cells, eukaryotic cells or bacteriophages. The prokaryotic cells may be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc. The eukaryotic cells may be fungi including Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, insect cells such as armyworms, plant cells such as tobacco, mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc. In some embodiments, the recombinant cells of the present invention are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.
[0074] It should be noted that the "suitable conditions" described in the specification of this application refer to conditions suitable for the expression of the antibody or antigen-binding fragment described in this application. It is easy for those skilled in the art to understand that the conditions suitable for the expression of the antibody or antigen-binding fragment include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell states, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the antibody or antigen-binding fragment according to the specific environment of the laboratory.
[0075] In another aspect of the present invention, the present invention proposes an immunoconjugate, comprising the above-mentioned antibody or antigen-binding fragment, and a therapeutic agent. As mentioned above, the antibody or antigen-binding fragment of the embodiment of the present invention can effectively bind to CD155 protein and block CD155 protein from binding to its receptor. Therefore, the immunoconjugate comprising the antibody or antigen-binding fragment can also bind to human or monkey CD155 protein, and the immunoconjugate has a good effect of preventing and / or treating CD155-mediated diseases, and does not induce apoptosis of CD155-positive cells, has low toxicity and side effects, and has higher safety.
[0076] In one aspect of the present invention, the present invention proposes a composition, including the above-mentioned antibody, nucleic acid molecule, expression vector or recombinant cell. As mentioned above, the antibody or antigen binding fragment of some specific embodiments of the present invention can effectively bind to CD155 protein, and block CD155 protein from binding to its receptor, and will not induce CD155 positive cell apoptosis. Therefore, the composition containing the above-mentioned substances can also effectively block CD155 protein from binding to its receptor. The antibody or antigen binding fragment has a good effect of preventing and / or treating CD155-mediated diseases, and will not induce CD155 positive cell apoptosis. The type of the composition is not particularly limited and can be a food composition or a pharmaceutical composition.
[0077] The compositions of the present invention may also be administered in combination with each other or with one or more other therapeutic compounds, for example, in combination with a chemotherapeutic agent. Therefore, the composition may also contain a chemotherapeutic agent. The antibody or antigen binding fragment thereof or immunoconjugate of the present invention may also be combined with a second therapeutic agent, exemplary agents of which include but are not limited to other agents that inhibit CD155 activity (including other antibodies or antigen binding fragments thereof, peptide inhibitors, small molecule antagonists, etc.) and / or agents that interfere with CD155 upstream or downstream signal transduction.
[0078] It should be noted that the composition includes combinations separated in time and / or space, as long as they can work together to achieve the purpose of the present invention. For example, the components contained in the composition can be administered to the subject as a whole, or separately. When the components contained in the composition are administered to the subject separately, each component can be administered to the subject simultaneously or sequentially.
[0079] In another aspect of the present invention, the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment thereof, nucleic acid molecule, expression vector, recombinant cell or composition in the preparation of a drug, which is used to prevent and / or treat CD155-related diseases. As mentioned above, the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to CD155 protein and block CD155 protein from binding to its receptor, and will not induce apoptosis of CD155-positive cells. Therefore, the drug containing the above-mentioned substance can also effectively block CD155 protein from binding to its receptor, and the antibody or antigen-binding fragment has a good effect of preventing and / or treating CD155-mediated diseases, and will not induce apoptosis of CD155-positive cells.
[0080] According to some specific embodiments of the present invention, the use of the above-mentioned preparation of medicines may also include at least one of the following additional technical features:
[0081] According to some specific embodiments of the present invention, the CD155-related disease is cancer, autoimmune disease, transplant rejection or infectious disease.
[0082] According to some specific embodiments of the present invention, the cancer includes at least one of melanoma, lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma and head and neck cancer.
[0083] According to some specific embodiments of the present invention, the infectious disease includes but is not limited to HIV virus infection and / or hepatitis B virus infection.
[0084] In another aspect of the present invention, the present invention proposes a drug, including the above-mentioned antibody nucleic acid molecule, expression vector, recombinant cell or composition. As mentioned above, the antibody or antigen binding fragment of some specific embodiments of the present invention can effectively bind to CD155 protein, and block CD155 protein from binding to its receptor, and will not induce apoptosis of CD155 positive cells. Therefore, a drug containing an effective amount of the antibody active ingredient or a series of substances thereof can also effectively block CD155 protein from binding to its receptor, and the antibody or antigen binding fragment has a good effect of preventing and / or treating CD155-mediated diseases, and will not induce apoptosis of CD155 positive cells.
[0085] According to some specific embodiments of the present invention, the above-mentioned medicine may further include at least one of the following additional technical features:
[0086] According to some specific embodiments of the present invention, the drug is used to treat or prevent CD155-related diseases.
[0087] According to some specific embodiments of the present invention, the CD155-related disease is cancer, autoimmune disease, transplant rejection or infectious disease.
[0088] According to some specific embodiments of the present invention, the cancer includes at least one of melanoma, lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma and head and neck cancer.
[0089] According to some specific embodiments of the present invention, the infectious disease includes but is not limited to HIV virus infection and / or hepatitis B virus infection.
[0090] According to some specific embodiments of the present invention, a pharmaceutically acceptable carrier may also be included.
[0091] As used herein, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity on humans and / or animals and can be accepted by humans and / or animals.
[0092] As used herein, "pharmaceutically acceptable" ingredients are suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), i.e., substances with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
[0093] The medicine of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Usually, the drug preparation should match the mode of administration, wherein the mode of administration can be oral administration, nasal administration, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration or intraperitoneal administration. The dosage form of the medicine of the present invention is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent. For example, it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The medicine is preferably manufactured under sterile conditions.
[0094] The effective amount of the active ingredient of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, several divided doses may be administered daily, or the dose may be reduced proportionally, depending on the urgency of the treatment situation.
[0095] Of course, the anti-CD155 antibody herein can also be made into a part of a kit or other diagnostic reagent as required.
[0096] In one aspect of the present invention, the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment in the preparation of a kit for detecting CD155. As mentioned above, the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD155 protein and block the binding of the CD155 protein to its receptor. Therefore, the antibody or antigen-binding fragment can be used to prepare a kit for detecting CD155 protein, and the kit can effectively detect CD155 protein qualitatively or quantitatively.
[0097] In another aspect of the present invention, the present invention proposes a kit for detecting CD155, the kit containing the above-mentioned antibody or antigen-binding fragment thereof. As mentioned above, the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD155 protein and block the CD155 protein from binding to its receptor. Therefore, the kit containing the antibody or antigen-binding fragment can effectively detect the CD155 protein qualitatively or quantitatively. The kit provided by the present invention can be used, for example, for immunoblotting, immunoprecipitation, etc., which involve using CD155 antigen and antibody specific binding properties to detect the kit. These kits may contain any one or more of the following: antagonists, anti-CD155 antibodies or drug reference materials; protein purification columns; immunoglobulin affinity purification buffers; cell determination diluents; instructions or literature, etc. Anti-CD155 antibodies can be used for different types of diagnostic tests, for example, various diseases or the presence of drugs, toxins or other proteins can be detected in vitro or in vivo. For example, the serum or blood of the subject can be tested to test related diseases. Such related diseases may include CD155 related diseases, such as cancer, autoimmune disease, transplant rejection or infectious diseases, wherein the cancer includes at least one of melanoma, lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma and head and neck cancer. Of course, the antibodies provided herein can also be used for radioimmunoassay and radioimmunotherapy of the above-mentioned diseases.
[0098] The kit may also include conventional reagents for detecting CD155, such as coating solution and the like.
[0099] The present invention also relates to a method for preventing and / or treating CD155-related diseases, comprising administering an effective amount of at least one of the antibodies or antigen-binding fragments thereof, nucleic acid molecules, expression vectors, recombinant cells, immunoconjugates and compositions of the present invention to a patient.
[0100] The "patient" or "subject" referred to in the present invention generally refers to a mammal, such as a primate and / or a rodent, in particular a human or a mouse.
[0101] The sequence descriptions involved in the present invention are shown in Table 1.
[0102] Table 1: Amino acid sequence description
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115] The present invention will be described in detail below through examples. In the examples or test examples, experimental methods without specific conditions are all carried out under conventional conditions.
[0116] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0117] Example 1: Preparation of antibodies
[0118] This example is used to obtain a murine monoclonal antibody against human CD155, wherein purified recombinant CD155 extracellular region Fc fusion protein (CD155-Fc) (a fusion protein of the recombinant CD155 extracellular region and hIgG1-Fc, whose amino acid sequence is shown in SEQ ID NO: 75) is used as an antigen to immunize Balb / c mice (9 weeks old, purchased from Shanghai Lesk, weighing about 20 g).
[0119] Immunized mice were immunized three times with purified antigen and complete Freund's adjuvant, and the immune response was detected after bleeding from the tail vein. The serum was screened by ELISA and flow cytometry through routine operation steps to obtain mice with anti-human CD155 immunoglobulin. The spleen cells of the mice with the highest anti-CD155 immunoglobulin were taken out and fused with mouse myeloma cells SP2 / 0 cells (ATCC No. CRL-1581). The fused hybridoma cells were screened for antibodies to obtain mouse monoclonal antibodies. More detailed experimental steps are as follows:
[0120] The total number of candidate hybridoma cells was cultured to 10 6 The cells were collected by centrifugation at 800 rpm for 10 minutes, and the total RNA of the hybridoma cells was extracted using a Trizol kit (Invitrogen); the total RNA was used as a template for reverse transcription to synthesize a cDNA library (Invitrogen), and the cDNA was used as a template for PCR amplification of the corresponding variable region nucleic acid sequence in the hybridoma cells. The primer sequences used in the PCR amplification reaction were complementary to the first framework region of the antibody variable region, or the signal peptide region and the constant region (for details, please refer to Larrick, JW, et al., (1990) Scand. J. Immunol., 32, 121-128 and Coloma, JJ et al., (1991) BioTechniques, 11, 152-156). The reaction system and process of PCR amplification are as follows: in a 50 μL reaction system, add 2 μL of the above cDNA, 5 μL of 10×PCR buffer, 2 μL of upstream and downstream primers (5 μmol), 2 μL of dNTP, 1 μL of Taq enzyme (Takara, Ex Taq), and 38 μL of H2O; pre-denature at 95°C for 5 min, enter temperature cycle, and perform PCR amplification. The reaction conditions are: denaturation at 94°C for 30S, annealing at 58°C for 45S, extension at 72°C for 50S, a total of 32 cycles, and then extension at 72°C for 7min. After sequencing the amplified product, the heavy chain and light chain variable region sequences of the mouse monoclonal antibody are obtained (the amino acid sequence is shown in SEQID NO:53-54).
[0121] Example 2: Detection of binding activity of mouse CD155 antibody
[0122] Flow cytometry experiments were used to detect the binding properties of CD155 antibodies. Human CD155 protein (CHO-K1-human CD155) and monkey CD155 protein (CHO-K1-Rhesus CD155) were overexpressed in CHO-K1 cells (ATCC number). The strength of the detection signal after adding the mouse antibody obtained in Example 1 was used to determine the binding properties of the antibody and CD155. The specific experimental operation was as follows:
[0123] HEK293T cells were cultured at 5 × 10 5Cells / well were plated in six-well plates and cultured overnight in DMEM medium without double antibodies. The culture medium was discarded before transfection and 1 mL of fresh DMEM medium without double antibodies was added. pLVX-EF1a-CD155-IRES-puro (nucleotide sequence SEQ ID NO: 45 encoding human CD155 protein) or pLVX-EF1a-cynomolgusCD155-IRES-puro (nucleotide sequence SEQ ID NO: 46 encoding Rhesus CD155 protein) was added to 200 μL serum-free DMEM medium with pMD2G and psPAX2 vectors (3 μg in total) at a ratio of 2: 1: 1, and then 12 μg of polyetherimide (PEI, Polysciences Co., Ltd.) was added, wherein the restriction sites of pLVX-EF1a-IRES-puro vector were between EcoRI and BamHI. After mixing, let stand for 16 minutes, and then all the liquid was added to the above-mentioned six-well plate with HEK293T cells. After 6 hours of culture, the culture medium was discarded and fresh complete DMEM medium was added for culture. After 48 hours of transfection, the cell culture supernatant was collected and filtered through a 0.45 μm filter (Millipore) to obtain the virus supernatant. The obtained different virus supernatants were added to 1×10 4 In a 6-well plate of CHO-K1 cells, add polybrene (Sigma) at a final concentration of 4 μg / mL and culture for 12 hours. Then discard the supernatant and add fresh complete DMEM medium. The resulting cells are CHO-K1-CD155 or CHO-K1-Rhesus CD155 cells.
[0124] The CHO-K1-human CD155 or CHO-K1-Rhesus CD155 cells were diluted to 2×10 6 / mL, added to a 1.5mL EP tube at a volume of 100μL / tube, and 10μL / tube goat serum (purchased from Shanghai Biotech) was added thereto, and blocked at 4℃ for 30min. Different concentrations of CD155 antibody were added and incubated at 4℃ for 30min. 1mL PBS was added to the EP tube, centrifuged at 4℃, 3500rpm×5min, the supernatant was discarded, and the precipitate was washed with PBS again. After centrifugation, the supernatant was discarded, the cells were resuspended with 100μL / tube PBS, and 0.1μL / tube Alexa-647-labeled goat anti-mouse antibody secondary antibody (Biolegend) was added thereto, and incubated at 4℃ for 30min in the dark. Wash twice with PBS, and discard the supernatant after centrifugation. The cells were resuspended with 200μL / tube PBS and detected by flow cytometry, in which IgG (purchased from Biolegend) was used as a control, Figure 1It was shown that the murine antibody (mutgi1005) of the present invention can bind to human and monkey CD155 proteins.
[0125] Example 3: Detection of blocking activity of mouse CD155 antibody
[0126] The CD155 antibody blocks the signaling pathway between CD155 and its receptors TIGIT, CD96, and CD226 by binding to the extracellular region of CD155. Flow cytometry experiments are used to detect the blocking effect of CD155 antibody on the binding of CD155 to its receptors. The specific experimental procedures are as follows:
[0127] The CHO-K1-human CD155 cells obtained in Example 2 (same as above) were diluted to 2×10 6 / mL, add 100μL / tube to 1.5mL EP tube, add 10μL / tube mouse serum, block at 4℃ for 30min; add different concentrations of CD155 antibody after blocking, incubate at 4℃ for 30min; then add 2μg / tube TIGIT extracellular region Fc fusion protein (TIGIT-Fc, SEQ ID NO:76, expressed in this laboratory), 4μg / tube CD96 extracellular region Fc fusion protein (CD96-Fc, SEQ ID NO:77, expressed in this laboratory), 2μg / tube CD226 extracellular region Fc fusion protein (CD226-Fc, SEQ ID NO:78, expressed in this laboratory), incubate at 4℃ for 30min. Add 1mL PBS to the above EP tube, centrifuge at 4℃ for 5min at 3500rpm, discard the supernatant, and wash again with PBS. After centrifugation, discard the supernatant, resuspend the cells with 100 μL / tube PBS, and then add 1 μL / tube 647-labeled mouse anti-human antibody secondary antibody (HP6017, Biolegend) to it, and incubate at 4°C in the dark for 30 minutes. Wash twice with PBS, centrifuge and discard the supernatant. Resuspend the cells with 200 μL / tube PBS and detect them by flow cytometry, in which IgG (purchased from Biolegend) was used as the control antibody. The results are shown in Figure 2 As shown, it can be seen that the murine CD155 antibody (mutgi1005) of the present invention is able to block the binding of CD155 to TIGIT, CD96 and CD226.
[0128] Example 4: Mouse CD155 antibody blocking activity detection experiment
[0129] ELISA experiments were used to detect the effect of antibodies on the binding of CD155 to its receptors TIGIT, CD96, and CD226. The specific experiments are as follows:
[0130] CD155-His tag fusion protein (purchased from Acro) was diluted to 5 μg / mL with PBS buffer, added to a 96-well plate at a volume of 100 μL / well, and placed at 4°C overnight. The PBS buffer in the 96-well plate was aspirated, and the plate was washed 6 times with PBST (pH7.2 PBS containing 0.1% Tween 20) buffer, and then 200 μL / well PBS / 10% BSA was added, and incubated at 37°C for 2 hours for blocking. The blocking solution was removed, and the plate was washed 6 times with PBST, and then the mouse CD155 antibody to be tested, 5 μg / mL TIGIT-Avi tag (purchased from Acro), 3.2 μg / mL CD96-Avi tag (purchased from Acro), or 10 μg / mL LCD226-Avi tag (purchased from Acro) diluted to an appropriate concentration with PBST / 0.05% BSA were added, a total of 100 μL / well, and incubated at 37°C for 1 hour. Remove the reaction system, wash the plate with PBST 6 times, dilute HRP (horseradish peroxidase) labeled strreptavidin secondary antibody (purchased from Southern biotech) with PBST / 0.05% BSA at 100 μL / well, and incubate at 37°C for 1 hour. Wash the plate with PBST 6 times, add 80 μL / well TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, add 80 μL / well 4M sulfuric acid to terminate the reaction, and use mIgG (purchased from Biolegend) and SKII4 (purchased from Biolegend) as controls to read the absorbance value at 450 mm using an enzyme reader. The results are as follows: Figure 3 The results show that the mouse CD155 antibody (Mutgi1005) of the present invention can block the binding of CD155 to its receptors TIGIT, CD96 and CD226.
[0131] Example 5: Chimeric CD155 Antibody Flow Cytometry Binding Experiment
[0132] The CHO-K1-human CD155 and CHO-K1-Rhesus CD155 cells obtained in Example 2 were diluted to 2×10 6 / mL, add to a 1.5mL EP tube at a volume of 100μL / tube, add 10μL / tube of mouse serum, and block at 4°C for 30min. Add different concentrations of mutgi1005-hIgG1 or mutgi1005-hIgG4 CD155 chimeric antibody (the light chain variable region and heavy chain variable region of the mouse antibody obtained in Example 1 are fused with human wild-type IgG1 or IgG4, respectively, as shown in SEQ ID NO: 69-72), and incubate at 4°C for 30min. Add 1mL PBS to the EP tube, centrifuge at 4°C, 3500rpm×5min, discard the supernatant, and wash again with PBS. After centrifugation, discard the supernatant, resuspend the cells with 100μL / tube PBS, add 1μL / tube Alexa-647-labeled mouse anti-human antibody secondary antibody (HP6017, Biolegend), and incubate at 4°C in the dark for 30min. Wash twice with PBS, and discard the supernatant after centrifugation. Resuspend the cells with 200 μL / tube PBS and detect them by flow cytometry. The results are as follows: Figure 4 As shown, it is further demonstrated that the chimeric antibody of the present invention can bind to human or monkey CD155 protein.
[0133] Example 6: Antibody humanization and affinity maturation experiments
[0134] With reference to the CD155 antibody heavy chain variable region sequence (as shown in SEQ ID NO: 53) and light chain variable region sequence (as shown in SEQ ID NO: 54) obtained in Example 1, the MOE software was used to design and select the best humanized template matching its non-CDR region. The mouse antibody CDR region was transplanted to the selected humanized template to replace the CDR region of the human template to obtain a humanized antibody. Then, based on the three-dimensional structure of the mouse antibody, the buried residues, the residues that directly interacted with the CDR region, and the residues in the FR region that had an important influence on the conformation of VL and VH were reversely mutated to obtain the humanized antibody. The sequence of the heavy chain variable region of the humanized CD155 antibody (tgi1005 V0-hIgG1 / 4) is shown in SEQ ID NO: 63, and the light chain variable region sequence is shown in SEQ ID NO: 64.
[0135] By randomly mutating the CD155 antibody CDR region, an affinity-matured antibody is obtained. The sequence of the heavy chain variable region of the affinity-matured CD155 antibody is shown in SEQ ID NO: 25, and the sequence of the light chain variable region is shown in SEQ ID NO: 26; or, the sequence of the heavy chain variable region of the affinity-matured CD155 antibody is shown in SEQ ID NO: 27, and the sequence of the light chain variable region is shown in SEQ ID NO: 28; or, the sequence of the heavy chain variable region of the affinity-matured CD155 antibody is shown in SEQ ID NO: 29, and the sequence of the light chain variable region is shown in SEQ ID NO: 30; or, the sequence of the heavy chain variable region of the affinity-matured CD155 antibody is shown in SEQ ID NO: 31, and the sequence of the light chain variable region is shown in SEQ ID NO: 32. The specific sequences are shown in Table 1 or 2.
[0136] Table 2:
[0137]
[0138] Example 7: Affinity matured humanized CD155 antibody binding activity detection experiment
[0139] ELISA experiments were used to detect the binding properties of the affinity matured humanized CD155 antibody obtained in Example 6. CD155-His tag fusion protein (purchased from Acro) and Rhesus CD155-His tag fusion protein (purchased from Acro) were coated into 96-well plates, and the strength of the detection signal after the addition of the antibody was used to determine the binding properties of the antibody to human and monkey CD155.
[0140] Dilute CD155-His tag fusion protein and Rhesus CD155-His tag fusion protein to 2μg / mL with PBS buffer, add 100μL / well to a 96-well plate, and place overnight at 4°C. Aspirate the PBS buffer in the 96-well plate, wash the plate 6 times with PBST (pH7.2 PBS containing 0.1% Tween 20) buffer, add 200μL / well PBS / 10% BSA, and incubate at 37°C for 2h for blocking. After removing the blocking solution, wash the plate 6 times with PBST, add 100μL / well of affinity matured humanized CD155 antibody to be tested diluted to an appropriate concentration with PBST / 0.05% BSA, and incubate at 37°C for 1h. Remove the reaction system, wash the plate with PBST 6 times, dilute HRP (horseradish peroxidase) labeled mouse anti-human IgG (Fab specific) secondary antibody (Sigma) with PBST / 0.05% BSA at 100 μL / well, and incubate at 37°C for 1 hour. Wash the plate with PBST 6 times, add 80 μL / well TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, add 80 μL / well 4M sulfuric acid to terminate the reaction, wherein hIgG1 (purchased from Biolegend and NB1088-hIgG1 (SEQ ID NO: 79 and 81) and NB1088-hIgG4 (SEQ ID NO: 80 and 81) patented antibodies expressed in this laboratory) was used as the control antibody. The absorbance value was read at 450 mm using an enzyme reader. The results are as shown in the figure. Figure 5 As shown, LALA refers to L234A and L235A mutations in the hIgG1 constant region. The affinity-matured humanized CD155 antibody of the present invention can bind to human and monkey CD155, and the binding activity of the affinity-matured antibody is higher than that of the antibody without affinity maturation.
[0141] Example 8: Affinity matured humanized CD155 antibody blocking activity detection experiment
[0142] ELISA experiments were used to detect the effect of the affinity-matured humanized CD155 antibody obtained in Example 6 on the binding of CD155 to its receptor.
[0143] CD155-His tag fusion protein (purchased from Acro) was diluted to 5 μg / mL with PBS buffer, added to a 96-well plate at a volume of 100 μL / well, and placed at 4°C overnight. The PBS buffer in the 96-well plate was aspirated, and the plate was washed 6 times with PBST (pH 7.2 PBS containing 0.1% Tween 20) buffer, and then 200 μL / well PBS / 10% BSA was added and incubated at 37°C for 2 hours for blocking. Remove the blocking solution, wash the plate with PBST 6 times, add 100 μL / well of the affinity-matured humanized CD155 antibody to be tested diluted to an appropriate concentration with PBST / 0.05% BSA, and add 5 μg / mL TIGIT-Avi tag (purchased from Acro), 3.2 μg / mL CD96-Avi tag (purchased from Acro) and 10 μg / mL CD226-Avi tag (purchased from Acro) to the above antibodies, and incubate at 37°C for 1 hour. After the incubation, remove the reaction system, wash the plate with PBST 6 times, dilute the HRP (horseradish peroxidase) labeled Avidin secondary antibody with PBST / 0.05% BSA with 100 μL / well, and incubate at 37°C for 1 hour. After washing the plate with PBST 6 times, add 80 μL / well TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, and add 80 μL / well 4M sulfuric acid to terminate the reaction. The absorbance was read at 450 nm using an ELISA reader. Figure 7 As shown, the affinity-matured humanized CD155 antibody of the present invention can block the binding of CD155 to TIGIT, CD96, and CD226.
[0144] Example 9: Flow cytometry binding experiment of affinity matured humanized CD155 antibody
[0145] The CHO-K1-human CD155 and CHO-K1-Rhesus CD155 cells obtained in Example 2 were diluted to 2×10 6 / mL, add it to a 1.5mL EP tube at a volume of 100μL / tube, add 10μL / tube of rat serum thereto, and block it at 4℃ for 30min. Add different concentrations of the affinity matured humanized CD155 antibody obtained in Example 6 and incubate at 4℃ for 30min. Add 1mL PBS to the EP tube, centrifuge at 4℃, 3500rpm×5min, discard the supernatant, and wash it again with PBS; after centrifugation, discard the supernatant, resuspend the cells with 100μL / tube PBS, add 1μL / tube Alexa-647-labeled rat anti-human antibody secondary antibody (Biolegend), and incubate at 4℃ in the dark for 30min. Wash twice with PBS, discard the supernatant after centrifugation. Resuspend the cells with 200μL / tube PBS and detect them by flow cytometry, wherein hIgG1 is used as the control antibody. The experimental results are as follows Figure 6 As shown, it is further demonstrated that the affinity matured humanized antibody of the present invention is able to bind to CD155.
[0146] Example 10: Effect of affinity-matured humanized CD155 antibody on apoptosis of U-937-CD155 cells
[0147] Flow cytometry experiments were used to detect the functional properties of the affinity-matured humanized CD155 antibody obtained in Example 6. The human CD155 protein (U-937-CD155) was overexpressed in U937 cells (ATCC No. CRL-1593.2) using the pLVX-EF1a-IRES-puro plasmid. The above-mentioned antibody was added and incubated for 4 hours, and then 7-AAD was added. The strength of the 7-AAD signal was detected to determine the functional properties of the CD155 antibody in affecting the apoptosis of U-937-CD155 cells.
[0148] HEK293T cells were cultured at 5×10 5 Cells / well were plated in a six-well plate and cultured overnight in DMEM medium without dual antibodies. Before transfection, the medium was discarded and 1 mL of fresh DMEM medium without dual antibodies was added. pLVX-EF1a-CD155-IRES-pur (the coding sequence of human CD155 protein (SEQ ID NO: 45) was inserted between the restriction sites EcoRI and BamHI of the pLVX-EF1a-IRES-puro vector), pMD2G, and psPAX2 vector (3 μg in total) were added to 200 μL serum-free DMEM medium at a ratio of 2:1:1, and 12 μg of polyetherimide (PEI, Polysciences Co., Ltd.) was added. After mixing, the mixture was allowed to stand for 16 minutes, and then all the liquid was added to the above-mentioned six-well plate with HEK293T cells. After 6 hours of culture, the culture medium was discarded and fresh complete DMEM culture medium was added for culture. After 48 hours of transfection, the cell culture supernatant was collected and filtered through a 0.45 μm filter (Millipore) to obtain the viral supernatant. All the viral supernatants were added to a 1×10 4 In a 6-well plate of U-937 cells, add polybrene (Sigma) at a final concentration of 4 μg / mL and culture for 12 hours. Then discard the supernatant and add fresh complete IMDM medium. The resulting cells are U-937-CD155 cells.
[0149] Dilute U-937-CD155 cells to 2 × 10 in complete IMDM. 5 / mL, added to a 96-well round-bottom plate at a volume of 100 μL / tube, added the affinity-matured humanized CD155 antibody mentioned above, and incubated at 37°C, 5% CO2 for 4 hours. Added 1 μg / tube of 7-AAD, the cell suspension was transferred to a flow tube, and detected by flow cytometry. The results are shown in Figure 8 As shown, it is further shown that the affinity matured humanized CD155 antibodies of the present invention have different functional properties, among which v0 can promote apoptosis of U-937-CD155 cells, while v20, v28, and v40 do not induce apoptosis.
[0150] Example 11: Effect of affinity-matured humanized CD155 antibody on anti-cancer activity in mice
[0151] The in vivo efficacy experiment was used to detect the anti-cancer function of the affinity-matured humanized CD155 antibody obtained in Example 6 in promoting immune reconstitution mice.
[0152] (1) On day 0, human PBMCs were transfused into NCG mice (purchased from Jicui Pharmaceutical) via tail vein, 1×10 7 Piece / piece;
[0153] (2) On day 4, NCG mice were subcutaneously injected with 1×10 6 tumor cells;
[0154] (2) on days 7, 10, 13, and 16, intraperitoneally injecting the affinity-matured humanized antibody into mice at a dose of 100 μg or 200 μg per mouse;
[0155] (3) The tumor volume was measured every 3 days (days 7, 10, 13, 16, 19, and 22) after injection of the above antibodies.
[0156] The results are as follows Fig. 9 As shown, it can be seen that the affinity-matured humanized CD155 antibody of the present invention can effectively inhibit tumor growth and has anti-cancer function.
[0157] Based on the experimental results of the above Examples 1-11, the antibodies obtained by the present invention can bind to human and monkey CD155 proteins; can effectively block the interaction between CD155 and its receptors TIGIT, CD96, and CD226; and can promote anti-cancer in immune reconstructed mice.
[0158] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
[0159] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0160] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. An anti-CD155 antibody or antigen-binding fragment, characterized in that: include: 1) the heavy chain variable region CDR1 shown in SEQ ID NO: 1, the heavy chain variable region CDR2 shown in SEQ ID NO: 2, the heavy chain variable region CDR3 shown in SEQ ID NO: 3, the light chain variable region CDR1 shown in SEQ ID NO: 4, the light chain variable region CDR2 shown in SEQ ID NO: 5, and the light chain variable region CDR3 shown in SEQ ID NO: 6: or 2) the heavy chain variable region CDR1 shown in SEQ ID NO: 7, the heavy chain variable region CDR2 shown in SEQ ID NO: 8, the heavy chain variable region CDR3 shown in SEQ ID NO: 9, the light chain variable region CDR1 shown in SEQ ID NO: 10, the light chain variable region CDR2 shown in SEQ ID NO: 11, and the light chain variable region CDR3 shown in SEQ ID NO: 12; or 3) the heavy chain variable region CDR1 shown in SEQ ID NO: 13, the heavy chain variable region CDR2 shown in SEQ ID NO: 14, the heavy chain variable region CDR3 shown in SEQ ID NO: 15, the light chain variable region CDR1 shown in SEQ ID NO: 16, the light chain variable region CDR2 shown in SEQ ID NO: 17, and the light chain variable region CDR3 shown in SEQ ID NO: 18; or 4) the heavy chain variable region CDR1 shown in SEQ ID NO: 19, the heavy chain variable region CDR2 shown in SEQ ID NO: 20, the heavy chain variable region CDR3 shown in SEQ ID NO: 21, the light chain variable region CDR1 shown in SEQ ID NO: 22, the light chain variable region CDR2 shown in SEQ ID NO: 23, and the light chain variable region CDR3 shown in SEQ ID NO:
24.
2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: include: i) a heavy chain variable region having an amino acid sequence that is at least 80% homologous to at least one of the amino acid sequences shown in SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and conservatively modified forms thereof; and / or ii) a light chain variable region, wherein the light chain variable region has an amino acid sequence that is at least 80% homologous to at least one of the amino acid sequences shown in SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, and their modified forms.
3. The antibody or antigen-binding fragment thereof according to claim 2, characterized in that: The heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homologous to the heavy chain variable region selected from i); the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homologous to the light chain variable region selected from ii).
4. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: include: 1) a heavy chain variable region as shown in SEQ ID NO: 25, and a light chain variable region as shown in SEQ ID NO: 26; or 2) a heavy chain variable region as shown in SEQ ID NO: 27, and a light chain variable region as shown in SEQ ID NO: 28; or 3) a heavy chain variable region as shown in SEQ ID NO: 29, and a light chain variable region as shown in SEQ ID NO: 30; or 4) a heavy chain variable region as shown in SEQ ID NO: 31, and a light chain variable region as shown in SEQ ID NO:
32.
5. The antibody or antigen-binding fragment according to claim 1, characterized in that The antibody contains at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a human antibody, a primate antibody or a mutant thereof; Optionally, the light chain constant region and heavy chain constant region of the antibody are both derived from human IgG antibody or a mutant thereof; Optionally, the light chain constant region and heavy chain constant region of the antibody are both derived from human IgG1 antibody, human IgG4 antibody or mutants thereof; Optionally, the antibody has a heavy chain constant region with an amino acid sequence as shown in SEQ ID NO:41, 42 or 43 and / or a light chain constant region with an amino acid sequence as shown in SEQ ID NO:
44.
6. The antibody or antigen-binding fragment according to claim 5, characterized in that A heavy chain having an amino acid sequence shown in any one of SEQ ID NOs: 33, 35, 37 and 39 and a light chain having an amino acid sequence shown in any one of SEQ ID NOs: 34, 36, 38 and 40.
7. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody is a monoclonal antibody or a chimeric antibody.
8. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody is a mouse antibody, a humanized antibody, a human modified antibody or a human antibody.
9. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody is Fv, single-chain antibody (scFv), Fab, Fab', Fab'-SH or F(ab')2.
10. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody or antigen-binding fragment thereof is capable of binding to the amino acid sequence shown in SEQ ID NO: 73 and / or 74.
11. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the antibody or antigen-binding fragment according to any one of claims 1 to 10.
12. The nucleic acid molecule according to claim 11, characterized in that The nucleic acid molecule is DNA.
13. An expression vector, characterized in that: Carrying the nucleic acid molecule according to any one of claims 11-12.
14. A recombinant cell, characterized in that Carrying the nucleic acid molecule according to any one of claims 11-12, the expression vector according to claim 13, or being capable of expressing the antibody or antigen-binding fragment according to any one of claims 1-10.
15. The recombinant cell according to claim 14, characterized in that The recombinant cell is obtained by introducing the expression vector according to claim 13 into a host cell.
16. The recombinant cell according to claim 15, characterized in that The expression vector is introduced into the host cell by electrotransduction.
17. The recombinant cell according to claim 14, characterized in that The recombinant cell is a eukaryotic cell.
18. The recombinant cell according to claim 14, characterized in that The recombinant cell is a mammalian cell.
19. An immunoconjugate, characterized in that The invention comprises the antibody or antigen-binding fragment according to any one of claims 1 to 10, and a therapeutic agent.
20. A composition, characterized in that The method comprises the antibody according to any one of claims 1 to 10, the nucleic acid molecule according to any one of claims 11 to 12, the expression vector according to claim 13, or the recombinant cell according to any one of claims 14 to 18.
21. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, the nucleic acid molecule according to any one of claims 11 to 12, the expression vector according to claim 13, the recombinant cell according to any one of claims 14 to 18 or the composition according to claim 20 in the preparation of a medicament for preventing and / or treating at least one of melanoma, lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma and head and neck cancer.
22. A drug, characterized in that The method comprises the antibody according to any one of claims 1 to 10, the nucleic acid molecule according to any one of claims 11 to 12, the expression vector according to claim 13, the recombinant cell according to any one of claims 14 to 18, or the composition according to claim 20.
23. Use of the antibody or antigen-binding fragment according to any one of claims 1 to 10 in preparing a kit for detecting CD155.
24. A kit for detecting CD155, characterized in that: The kit contains the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.
